Table 4.
Clinicopathological and molecular characteristics of G1, G2, and G3 in this study.
| Clinicopathologic characteristics | Number of patients (N=3937) | G1: RNF43 codon 659-mutated, Non-class1 BRAF-mutated, and MSI-H, N (%) (N=34) | G2: Not G1 and G3, N (%) (N=3816) | G3: RNF43 Non-codon 659-mutated, Class 1 BRAF-mutated, and Non-MSI-H, N (%) (N=87) | P value (G1 vs. G2) | P value (G1 vs. G3) | P value (G2 vs. G3) |
|---|---|---|---|---|---|---|---|
| Age | <0.0001 | <0.0001 | 0.189 | ||||
| Young (years <50) | 1300 (33.02%) | 1 (2.94%) | 1261 (33.05%) | 38 (43.68%) | |||
| Intermediate (<70 years ≥50) | 1647 (41.83%) | 11 (32.35%) | 1605 (42.06%) | 31 (35.63%) | |||
| Elder (years≥70) | 963 (24.46%) | 22 (64.71%) | 923 (24.19%) | 18 (20.69%) | |||
| NA | 27 (0.69%) | 0 (0.00%) | 27 (0.71%) | 0 (0.00%) | |||
| Gender | 0.1876 | 0.2404 | 0.0647 | ||||
| Female | 1845 (46.86%) | 21 (61.76%) | 1782 (46.70%) | 42 (48.28%) | |||
| Male | 2030 (51.56%) | 13 (38.24%) | 1976 (51.78%) | 41 (47.13%) | |||
| NA | 62 (1.57%) | 0 (0.00%) | 58 (1.52%) | 4 (4.60%) | |||
| Primary tumor location | <0.0001 | <0.0001 | 0.541 | ||||
| Right | 916 (23.27%) | 30 (88.24%) | 867 (22.72%) | 19 (21.84%) | |||
| Left | 2090 (53.09%) | 1 (2.94%) | 2046 (53.62%) | 43 (49.43%) | |||
| NA | 931 (23.65%) | 3 (8.82%) | 903 (23.66%) | 25 (28.74%) | |||
| TNM stage | <0.0001 | 0.0087 | 0.0855 | ||||
| I | 425 (10.80%) | 4 (11.76%) | 406 (10.64%) | 15 (17.24%) | |||
| II | 743 (18.87%) | 18 (52.94%) | 704 (18.45%) | 21 (24.14%) | |||
| III | 1224 (31.09%) | 10 (29.41%) | 1190 (31.18%) | 24 (27.59%) | |||
| IV | 1375 (34.93%) | 1 (2.94%) | 1352 (35.43%) | 22 (25.29%) | |||
| NA | 170 (4.32%) | 1 (2.94%) | 164 (4.30%) | 5 (5.75%) | |||
| TUMOR_GRADE | <0.0001 | 0.0767 | 0.152 | ||||
| Well differentiated | 509 (12.93%) | 4 (11.76%) | 495 (12.97%) | 10 (11.49%) | |||
| Moderately differentiated | 1351 (34.32%) | 6 (17.65%) | 1318 (34.54%) | 27 (31.03%) | |||
| Moderate poorly differentiated | 110 (2.79%) | 1 (2.94%) | 105 (2.75%) | 4 (4.60%) | |||
| Poorly differentiated | 333 (8.46%) | 13 (38.24%) | 307 (8.05%) | 13 (14.94%) | |||
| NA | 1634 (41.50%) | 10 (29.41%) | 1591 (41.69%) | 33 (37.93%) | |||
| TMB | <0.0001 | <0.0001 | <0.0001 | ||||
| TMB-H | 858 (21.79%) | 34 (100.00%) | 789 (20.68%) | 35 (40.23%) | |||
| TMB-L | 2745 (69.72%) | 0 (0.00%) | 2700 (70.75%) | 45 (51.72%) | |||
| NA | 334 (8.48%) | 0 (0.00%) | 327 (8.57%) | 7 (8.05%) | |||
| MSI | <0.0001 | <0.0001 | 0.898 | ||||
| MSI-H | 34 (0.86%) | 34 (100.00%) | 0 (0.00%) | 0 (0.00%) | |||
| MSS | 2834 (71.98%) | 0 (0.00%) | 2768 (72.54%) | 66 (75.86%) | |||
| NA | 874 (22.20%) | 8 (23.53%) | 845 (22.14%) | 21 (24.14%) | |||
| BRAF status | <0.0001 | <0.0001 | >0.9999 | ||||
| BRAF mut | 329 (8.36%) | 34 (100.00%) | 289 (7.57%) | 6 (6.90%) | |||
| BRAF wild-type | 3608 (91.64%) | 0 (0.00%) | 3527 (92.43%) | 81 (93.10%) | |||
| BRAF mutation types | 0.0008 | <0.0001 | <0.0001 | ||||
| Class 1 | 224 (5.69%) | 34 (100.00%) | 190 (4.98%) | 0 (0.00%) | |||
| Class 2 | 9 (0.23%) | 0 (0.00%) | 9 (0.24%) | 0 (0.00%) | |||
| Class 3 | 40 (1.02%) | 0 (0.00%) | 40 (1.05%) | 0 (0.00%) | |||
| NA | 56 (1.42%) | 0 (0.00%) | 50 (1.31%) | 6 (6.90%) |